



## LETTER TO THE EDITOR

Journal of Pathology and Translational Medicine 2019; 53: 412-414  
<https://doi.org/10.4132/jptm.2019.09.27>

# JPTM

## Response to Comment on “Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis”

Jung-Soo Pyo, Nae Yu Kim<sup>1</sup>, Won Jin Cho<sup>2</sup>

Departments of Pathology and <sup>1</sup>Internal Medicine, Eulji University Hospital, Eulji University School of Medicine, Daejeon;  
<sup>2</sup>Department of Urology, Chosun University Hospital, Chosun University School of Medicine, Gwangju, Korea

This study aimed to elucidate the prognostic roles of claudin-1 immunohistochemistry in various malignant tumors through a meta-analysis. Data from all included studies were extracted by two independent authors (J.S.P. and N.Y.K.). Any disagreements for extracting data were resolved by consensus. In the present study, to review more articles, we used the narrow exclusion criteria. Therefore, discordance for the literature collection did not occur. We assessed the risk of bias for all included studies according to the Newcastle-Ottawa Scale. The detailed information was shown in Table 1. All data for survivals were a 5-year survival rate. If the extractable data only included the survival curve, survival rates at 5-year were obtained from the survival curve.

### ORCID

Jung-Soo Pyo: <https://orcid.org/0000-0003-0320-8088>

Nae Yu Kim: <https://orcid.org/0000-0002-0461-6385>

Won Jin Cho: <https://orcid.org/0000-0001-9827-5173>

### Conflicts of Interest

The authors declare that they have no potential conflicts of interest.

Received: September 23, 2019 Accepted: September 26, 2019

Corresponding Author: Won Jin Cho, MD

Department of Urology, Chosun University Hospital, Chosun University School of Medicine, 385 Pilmun-daero, Dong-gu, Gwangju 61453, Korea  
Tel: +82-62-220-3210, Fax: +82-62-232-3210, E-mail: [uro2097@gmail.com](mailto:uro2097@gmail.com)

**Table 1.** The Newcastle-Ottawa Scale for the quality assessment of eligible studies

Study	Selection			Demonstration that outcome of interest was not present at start of study	Comparability		Outcome		Score
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure		Comparability of cohorts on the basis of the design or analysis	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow-up of cohorts	
Ma et al. (2014) <sup>1</sup>	NA	NA	NA	*	*	*	*	*	5
Morohashi et al. (2007) <sup>2</sup>	NA	NA	NA	*	*	*	*	*	5
Matsuo et al. (2011) <sup>3</sup>	NA	NA	NA	*	*	*	*	*	5
Resnick et al. (2005) <sup>4</sup>	NA	NA	NA	*	-	*	*	*	4
Shibutani et al. (2013) <sup>5</sup>	NA	NA	NA	*	*	*	*	*	5
Yoshida et al. (2011) <sup>6</sup>	NA	NA	NA	*	*	*	*	*	5
Miyamoto et al. (2008) <sup>7</sup>	NA	NA	NA	*	*	*	*	*	5
Xiong et al. (2011) <sup>8</sup>	NA	NA	NA	*	*	*	*	*	5
Li et al. (2015) <sup>9</sup>	NA	NA	NA	*	*	*	*	*	5
Sappayatosok and Phattaratip (2015) <sup>10</sup>	NA	NA	NA	*	*	*	*	*	5
Fritzsche et al. (2008) <sup>11</sup>	NA	NA	NA	*	*	*	*	*	5
Shin et al. (2011) <sup>12</sup>	NA	NA	NA	*	*	*	*	*	5
Bouchagier et al. (2014) <sup>13</sup>	NA	NA	NA	*	*	*	*	*	5
Higashi et al. (2007) <sup>14</sup>	NA	NA	NA	*	-	*	*	*	4
Chae et al. (2014) <sup>15</sup>	NA	NA	NA	*	-	*	*	*	4
Chao et al. (2009) <sup>16</sup>	NA	NA	NA	*	-	*	*	*	4
Merikallo et al. (2011) <sup>17</sup>	NA	NA	NA	*	*	*	*	*	5
Zhang et al. (2013) <sup>18</sup>	NA	NA	NA	*	*	*	*	*	5
Huang et al. (2014) <sup>19</sup>	NA	NA	NA	*	*	*	*	*	5
Jung et al. (2011) <sup>20</sup>	NA	NA	NA	*	*	*	*	*	5
Tzelepi et al. (2008) <sup>21</sup>	NA	NA	NA	*	*	*	*	*	5
Hoellen et al. (2017) <sup>22</sup>	NA	NA	NA	*	*	*	*	*	5

NA, not available; \*, criteria satisfied; -, criteria not satisfied.

## REFERENCES

1. Ma F, Ding X, Fan Y, et al. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer. *PLoS One* 2014; 9: e112765.
2. Morohashi S, Kusumi T, Sato F, et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. *Int J Mol Med* 2007; 20: 139-43.
3. Matsuoka T, Mitomi H, Fukui N, et al. Cluster analysis of claudin-1 and -4, E-cadherin, and beta-catenin expression in colorectal cancers. *J Surg Oncol* 2011; 103: 674-86.
4. Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. *Mod Pathol* 2005; 18: 511-8.
5. Shibutani M, Noda E, Maeda K, Nagahara H, Ohtani H, Hirakawa K. Low expression of claudin-1 and presence of poorly-differentiated tumor clusters correlate with poor prognosis in colorectal cancer. *Anticancer Res* 2013; 33: 3301-6.
6. Yoshida T, Kinugasa T, Akagi Y, et al. Decreased expression of claudin-1 in rectal cancer: a factor for recurrence and poor prognosis. *Anticancer Res* 2011; 31: 2517-25.
7. Miyamoto K, Kusumi T, Sato F, et al. Decreased expression of claudin-1 is correlated with recurrence status in esophageal squamous cell carcinoma. *Biomed Res* 2008; 29: 71-6.
8. Xiong L, Wen Y, Miao X, Yang Z. Expressions of cell junction regulatory proteins and their association with clinicopathologic parameters in benign and malignant gallbladder lesions. *Am J Med Sci* 2011; 342: 388-94.
9. Li WJ, Zhang ZL, Yu XM, Cai XL, Pan XL, Yang XY. Expression of claudin-1 and its relationship with lymphatic microvessel generation in hypopharyngeal squamous cell carcinoma. *Genet Mol Res* 2015; 14: 11814-26.
10. Sappayatosok K, Phattaratatip E. Overexpression of claudin-1 is associated with Advanced clinical stage and invasive pathologic characteristics of oral Squamous Cell Carcinoma. *Head Neck Pathol* 2015; 9: 173-80.
11. Fritzsche FR, Oelrich B, Johannsen M, et al. Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. *Clin Cancer Res* 2008; 14: 7035-42.
12. Shin HI, Kim BH, Chang HS, Kim CI, Jung HR, Park CH. Expression of claudin-1 and -7 in clear cell renal cell carcinoma and its clinical significance. *Korean J Urol* 2011; 52: 317-22.
13. Bouchagier KA, Assimakopoulos SF, Karavias DD, et al. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival. *In Vivo* 2014; 28: 315-26.
14. Higashi Y, Suzuki S, Sakaguchi T, et al. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. *J Surg Res* 2007; 139: 68-76.
15. Chae MC, Park CK, Keum DY, Hwang I, Kwon KY, Jang BC. Prognostic significance of claudin 4 in completely resected adenocarcinoma of the lung. *Korean J Thorac Cardiovasc Surg* 2014; 47: 262-8.
16. Chao YC, Pan SH, Yang SC, et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. *Am J Respir Crit Care Med* 2009; 179: 123-33.
17. Merikallio H, Kaarteenaho R, Pääkkö P, et al. Impact of smoking on the expression of claudins in lung carcinoma. *Eur J Cancer* 2011; 47: 620-30.
18. Zhang Z, Wang A, Sun B, Zhan Z, Chen K, Wang C. Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. *J Cardiothorac Surg* 2013; 8: 95.
19. Huang J, Li J, Qu Y, et al. The expression of claudin 1 correlates with beta-catenin and is a prognostic factor of poor outcome in gastric cancer. *Int J Oncol* 2014; 44: 1293-301.
20. Jung H, Jun KH, Jung JH, Chin HM, Park WB. The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue. *J Surg Res* 2011; 167: e185-91.
21. Tzelepi VN, Tsamandas AC, Vlotinou HD, Vagianos CE, Scopa CD. Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. *Mod Pathol* 2008; 21: 22-30.
22. Hoellen F, Waldmann A, Banz-Jansen C, et al. Claudin-1 expression in cervical cancer. *Mol Clin Oncol* 2017; 7: 880-4.